Pancreatic Cancer: Novel Strategies of Diagnosis and Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: 26 August 2025 | Viewed by 627
Special Issue Editors
2. Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
3. Academy of Romanian Scientists, 050085 Bucharest, Romania
Interests: interdisciplinarity; comorbidities; cancer; molecular diagnostics; personalized treatments
Special Issues, Collections and Topics in MDPI journals
2. Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania
Interests: pancreatic cancer; molecular diagnostics; liquid biopsy; proteomics; genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic cancer is widely recognized as a highly aggressive form of cancer, exhibiting a 5-year survival rate of approximately 10%. The unfavorable prognosis primarily stems from delayed diagnosis during therapeutically advanced stages, as well as the poor success rate of oncological treatments. Recent research has concentrated on identifying potential non-invasive biomarkers that can be utilized to diagnose these patients at an early stage, evaluate their prognosis, and develop new therapeutic strategies. To date, a number of proteomic biomarkers, free-cell DNA, and microRNA have exhibited encouraging outcomes. Notwithstanding these findings, no biomarker has received approval for utilization in present-day practice.
A further crucial factor is the low incidence of pancreatic cancer, which, from a cost–benefit standpoint, precludes the implementation of screening strategies in the general population. Conversely, the recommended screening methods for specific subgroups with a significant likelihood of developing pancreatic cancer entail assessment using endoscopic ultrasound or magnetic resonance imaging, resulting in elevated expenses. Therefore, we highlight the importance of identifying non-invasive biomarkers that possess both high diagnostic accuracy and incur reasonable costs for monitoring these patients. MicroRNAs play a vital role in biological processes such as cell survival, apoptosis and proliferation, invasion, metastasis, and drug response, which highlights their potential as targets for diagnosis, prognosis, and therapy in patients with malignant disease. Furthermore, there is limited knowledge regarding the intercellular communication that is mediated by microRNA in pancreatic cancer. Researching the molecular changes that occur during the sequential progression from a premalignant lesion, such as pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasm, to pancreatic cancer will help us better comprehend the pancreatic oncogenesis process. Additionally, the connection between molecular marker values and clinical characteristics could help find biomarkers that can effectively identify people who are more likely to suffer from pancreatic cancer. This would enable the application of screening strategies in these groups.
The primary focus of this Special Issue is to increase the clinical focus on the pathogenesis of pancreatic cancer in order to achieve progress in innovative diagnostic and treatment strategies. We therefore want to provide novel data on patients who are diagnosed with pancreatic cancer, as well as those who possess risk factors associated with the development of this malignant condition.
Yours faithfully,
Dr. Camelia Cristina Diaconu
Dr. Gina Gheorghe
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- chronic pancreatitis
- pancreatic intraepithelial neoplasia
- gastroenterology
- clinical innovative diagnostic
- clinical treatment strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
